<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-6343</journal-id>
<journal-title><![CDATA[Farmacia Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Farm Hosp.]]></abbrev-journal-title>
<issn>1130-6343</issn>
<publisher>
<publisher-name><![CDATA[Grupo Aula Médica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-63432017000600678</article-id>
<article-id pub-id-type="doi">10.7399/fh.10834</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Cysteamine ophthalmic hydrogel for the treatment of ocular cystinosis]]></article-title>
<article-title xml:lang="es"><![CDATA[Hidrogel oftálmico de cisteamina para el tratamiento de la cistinosis ocular]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernández-Ferreiro]]></surname>
<given-names><![CDATA[Anxo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A3"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Luaces-Rodríguez]]></surname>
<given-names><![CDATA[Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz-Tomé]]></surname>
<given-names><![CDATA[Victoria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gil-Martínez]]></surname>
<given-names><![CDATA[María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez Ares]]></surname>
<given-names><![CDATA[María Teresa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Touriño Peralba]]></surname>
<given-names><![CDATA[Rosario]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Blanco-Méndez]]></surname>
<given-names><![CDATA[José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Barcia]]></surname>
<given-names><![CDATA[Miguel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A3"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Otero-Espinar]]></surname>
<given-names><![CDATA[Francisco Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lamas]]></surname>
<given-names><![CDATA[María Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Xerencia Xestión Integrada Santiago de Compostela (SERGAS) Pharmacy Service ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto de Investigación Sanitaria Clinical Pharmacology Group ]]></institution>
<addr-line><![CDATA[Santiago de Compostela ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,University of Santiago of Compostela (USC) Faculty of Pharmacy Pharmacology, Pharmacy and Pharmaceutical Technology Department]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Xerencia Santiago de Compostela (SERGAS) Pharmacy Service Ophthalmology Service]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>41</volume>
<numero>6</numero>
<fpage>678</fpage>
<lpage>687</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-63432017000600678&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-63432017000600678&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-63432017000600678&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Ocular cystinosis is a rare disease characterised by the deposition on the corneal surface of cystine crystals that hinder the eyesight of patients. Oral cysteamine is administered as cysteamine bitartrate; however, due to the lack of corneal vascularization it does not reach the cornea and must be administered by the topical ocular route. The aim of the present study was to determine the stability of an ophthalmic hydrogel of cysteamine under different preservation conditions during a follow-up of 30 days. This hydrogel could be prepared in hospital pharmacy services. Several physical and chemical parameters were assessed: osmolality, pH, and cysteamine concentration, which was measured using an ultra-performance liquid chromatography-tandem mass spectrometer (UPLC-MS/ MS) method. Descriptive tests were also performed, such as transparency measurements and microbiological assays in order to verify sterility. The results show that cysteamine hydrogel is stable over 30 days and should be preserved under refrigeration.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La cistinosis ocular es una enfermedad rara que se caracteriza por el depósito de cristales de cistina a nivel corneal, los cuales dificultan la visión de los pacientes. La cisteamina oral se administra en forma de cisteamina, pero esta no alcanza la córnea debido a la falta de vascularización corneal, por lo que es necesaria la aplicación tópica ocular. El objetivo del presente trabajo es determinar la estabilidad de un hidrogel oftálmico de cisteamina, potencialmente formulable en servicios de farmacia hospitalaria, conservado este bajo diferentes condiciones de almacenamiento durante un periodo de 30 días. Los parámetros físicos y químicos evaluados han sido la osmolalidad, el pH y la concentración de cisteamina, siendo esta última valorada mediante un método de cromatografía líquida de ultra alta presión, empleando un detector de masas en tándem (UPLC-MS/MS). Los ensayos descriptivos se han basado en la medición de la transparencia y los ensayos microbiológicos en la realización de pruebas de esterilidad. Los resultados obtenidos permiten concluir que el hidrogel de cisteamina es estable durante un periodo de 30 días, recomendándose que su conservación sea en nevera.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Cysteamine]]></kwd>
<kwd lng="en"><![CDATA[Ellman&#8217;s reagent]]></kwd>
<kwd lng="en"><![CDATA[Hyaluronic acid]]></kwd>
<kwd lng="en"><![CDATA[Mass spectrometry]]></kwd>
<kwd lng="en"><![CDATA[Ocular cystinosis]]></kwd>
<kwd lng="en"><![CDATA[Ophthalmic hydrogel]]></kwd>
<kwd lng="en"><![CDATA[Stability]]></kwd>
<kwd lng="es"><![CDATA[Ácido hialurónico]]></kwd>
<kwd lng="es"><![CDATA[Cisteamina]]></kwd>
<kwd lng="es"><![CDATA[Cistinosis]]></kwd>
<kwd lng="es"><![CDATA[Ocular]]></kwd>
<kwd lng="es"><![CDATA[Estabilidad]]></kwd>
<kwd lng="es"><![CDATA[Espectrometría de masas]]></kwd>
<kwd lng="es"><![CDATA[Hidrogel oftálmico]]></kwd>
<kwd lng="es"><![CDATA[Reactivo de Ellman]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gahl]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Thoene]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cystinosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2002</year>
<volume>347</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>111-21</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<collab>The Cystinosis Collaborative Research Group</collab>
<article-title xml:lang=""><![CDATA[Linkage of the gene for cystinosis to markers on the short arm of chromosome 17]]></article-title>
<source><![CDATA[Nat Genet]]></source>
<year>1995</year>
<volume>10</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>246-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Town]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jean]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cherqui]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Attard]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Forestier]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Whitmore]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis]]></article-title>
<source><![CDATA[Nat Genet]]></source>
<year>1998</year>
<volume>18</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>319-24</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burki]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ueber die Cystinkrankheit im Kleinkindesalter unter besonderer Berücksichtigung des Augenbefundes (About the Cystinosis in infancy with special reference to eye findings)]]></article-title>
<source><![CDATA[Ophthalmologica]]></source>
<year>1941</year>
<volume>101</volume>
<page-range>331-42</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gahl]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Kuehl]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Iwata]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lindblad]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kaiser-Kupfer]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops]]></article-title>
<source><![CDATA[Mol Genet Metab]]></source>
<year>2000</year>
<volume>71</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>100-20</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="">
<collab>Pubchem</collab>
<source><![CDATA[Cysteamine (C2H7NS)]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thoene]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Oshima]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Crawhall]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Olson]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>1976</year>
<volume>58</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>180-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brodin-Sartorius]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tête]]></surname>
<given-names><![CDATA[M-J]]></given-names>
</name>
<name>
<surname><![CDATA[Niaudet]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Antignac]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Guest]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ottolenghi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2012</year>
<volume>81</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>179-89</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaiser-Kupfer]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Caruso]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Minkler]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Gahl]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term ocular manifestations in nephropathic cystinosis]]></article-title>
<source><![CDATA[Arch Ophthalmol]]></source>
<year>1986</year>
<volume>104</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>706-11</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="">
<collab>Clinicaltrials</collab>
<source><![CDATA[Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis. Clinical Trial]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaiser-Kupfer]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Gazzo]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Datiles]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Caruso]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Kuehl]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Gahl]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized placebo-controlled trial of cysteamine eye drops in nephropathic cystinosis]]></article-title>
<source><![CDATA[Arch Ophthalmol]]></source>
<year>1990</year>
<volume>108</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>689-93</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="">
<source><![CDATA[Cystaran®. Prescribing information]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="">
<source><![CDATA[Cystadrops® 0,55% eye drops solution. Summary of product characteristics]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="">
<source><![CDATA[Cystadrops® 0,55% collyre en solutions. Protocole d&#8217;utilisation therapeutique et de recueil d&#8217;informations. Autorisation temporaire d&#8217;utilisation dite de cohorte]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="">
<collab>Clinical Trials Register</collab>
<source><![CDATA[Cysteamine Hydrochloride for nephropathic Cystinosis, open-label Phase III pivotal study (CYSTADROPS CHOC study)]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velásquez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El acceso global a los medicamentos en el contexto internacional actual]]></article-title>
<source><![CDATA[Biomédica]]></source>
<year>2011</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>162-3</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luaces-Rodríguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz-Tomé]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[González-Barcia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Silva-Rodríguez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Herranz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gil-Martínez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cysteamine polysaccharide hydrogels: study of extended ocular delivery and biopermanence time by PET imaging]]></article-title>
<source><![CDATA[Int J Pharm]]></source>
<year>2017</year>
<volume>528</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>714-22</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández Ferreiro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Luaces-Rodriguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[González Barcia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Otero Espinar]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lamas]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación de la biopermanencia ocular in vivo de tres formulaciones oftálmicas de cisteamina clorhidrato]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2016</year>
<numero>^sSupl1</numero>
<issue>^sSupl1</issue>
<supplement>Supl1</supplement>
<page-range>79</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guan]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Dwivedi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Matthees]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A simultaneous liquid chromatography/mass spectrometric assay of glutathione, cysteine, homocysteine and their disulfides in biological samples]]></article-title>
<source><![CDATA[J Pharm Biomed Anal]]></source>
<year>2003</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>251-61</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lawal]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Development of a cysteamine in situ gelling system for the treatment of corneal crystals in cystinosis]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Qi]]></surname>
<given-names><![CDATA[B-L]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Q-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Cai]]></surname>
<given-names><![CDATA[W-J]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[B-F]]></given-names>
</name>
<name>
<surname><![CDATA[Feng]]></surname>
<given-names><![CDATA[Y-Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Derivatization for liquid chromatography-mass spectrometry]]></article-title>
<source><![CDATA[TrAC Trends Anal Chem]]></source>
<year>2014</year>
<volume>59</volume>
<page-range>121-32</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ellman]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tissue sulfhydryl groups]]></article-title>
<source><![CDATA[Arch Biochem Biophys]]></source>
<year>1959</year>
<volume>82</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>70-7</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="book">
<collab>Royal Pharmaceutical Society of Great Britain Dept of Pharmaceutical</collab>
<source><![CDATA[The Pharmaceutical Codex: Principles and Practice of Pharmaceutics]]></source>
<year>1994</year>
<edition>Twelfth</edition>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Pharmaceutical Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrueco]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Escobar Rodríguez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[García Díaz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Gil Alegre]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[López Lunar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ventura Valares]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estabilidad de medicamentos en la práctica clínica: de la seguridad a la eficiencia]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2013</year>
<volume>37</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>175-7</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iwata]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Kuehl]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Reed]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
<name>
<surname><![CDATA[McCain]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Gahl]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Kaiser-Kupfer]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized clinical trial of topical cysteamine disulfide (cystamine) versus free thiol (cysteamine) in the treatment of corneal cystine crystals in cystinosis]]></article-title>
<source><![CDATA[Mol Genet Metab]]></source>
<year>1998</year>
<volume>64</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>237-42</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herreros]]></surname>
<given-names><![CDATA[JMA]]></given-names>
</name>
</person-group>
<source><![CDATA[Preparación de medicamentos y formulación magistral para oftalmología]]></source>
<year>2003</year>
<publisher-name><![CDATA[Ediciones Díaz de Santos]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Atienza]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[del Vayo]]></surname>
<given-names><![CDATA[CÁ]]></given-names>
</name>
</person-group>
<source><![CDATA[Formulación en farmacia pediátrica]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[A. Madrid Vicente editores]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="">
<collab>Asociación de Formulistas de Andalucia</collab>
<source><![CDATA[]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosin]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[NP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops]]></article-title>
<source><![CDATA[Clin Ophthalmol Auckl NZ]]></source>
<year>2013</year>
<volume>7</volume>
<page-range>2131-5</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="">
<collab>Convention USP</collab>
<source><![CDATA[Farmacopea de los Estados Unidos de América, USP 37, 2014: Formulario nacional, NF 32. United States Pharmacopeia]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="book">
<source><![CDATA[Practical Pharmaceutics. An International Guideline for the Preparation, Care and Use of Medicinal Products]]></source>
<year>2017</year>
<publisher-name><![CDATA[Yvonne Bouwman-Boer, V&#8217;lain Fenton-May, Paul Le Brun, editors]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
